PALIPERIDONE
Clinical safety rating: safe
Animal studies have demonstrated safety
Paliperidone is an atypical antipsychotic that exerts its effects primarily through antagonism of central dopamine D2 receptors and serotonin 5-HT2A receptors. It also antagonizes alpha-1 and alpha-2 adrenergic receptors, and H1 histaminergic receptors. Paliperidone is the major active metabolite of risperidone.
| Metabolism | Paliperidone is primarily eliminated unchanged via renal excretion. It undergoes limited hepatic metabolism via N-dealkylation and hydroxylation, with CYP2D6 and CYP3A4 partially involved. Approximately 80% of the dose is excreted unchanged in urine. |
| Excretion | Renal (approximately 80% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 11%) |
| Half-life | Approximately 23 hours for the extended-release oral formulation; provides steady trough concentrations with once-daily dosing |
| Protein binding | 74% bound, primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 487 L (approximately 7 L/kg for a 70 kg individual); indicates extensive tissue distribution |
| Bioavailability | Oral (extended-release): 28% relative to immediate-release tablet due to first-pass metabolism; intramuscular: 100% relative to oral solution |
| Onset of Action | Oral (extended-release): 24–48 hours; intramuscular (monthly): steady state achieved after 4–5 monthly injections |
| Duration of Action | Oral: 24 hours with once-daily dosing; intramuscular: approximately 4 weeks with monthly injections |
| Molecular Weight | 426.48 |
| Action Class | Atypical Antipsychotic |
6 mg orally once daily, with dose adjustments in 3 mg increments at intervals of 5 days or more; usual effective range 3-12 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For GFR 50-79 mL/min: maximum 6 mg daily; for GFR 10-49 mL/min: 3 mg daily; for GFR <10 mL/min: not recommended. |
| Liver impairment | No dose adjustment required for mild to moderate (Child-Pugh A or B) hepatic impairment; not studied in severe (Child-Pugh C) impairment. |
| Pediatric use | Adolescents (12-17 years, ≥51 kg): starting 3 mg once daily, increase by 3 mg every 5+ days up to 6 mg; <51 kg: starting 3 mg once daily, increase by 3 mg every 5+ days up to 3 mg. |
| Geriatric use | Initiate at 3 mg once daily; increase cautiously in 3 mg increments at intervals of 5 days or more; may require lower maintenance doses due to renal function decline. |
| 1st trimester | Limited human data; animal studies show increased fetal resorptions and developmental delays. Use only if benefit outweighs risk. |
| 2nd trimester | May cause extrapyramidal symptoms and/or withdrawal in neonates if used near term. Monitor for neonatal toxicity. |
| 3rd trimester | Risk of neonatal extrapyramidal symptoms, agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder. Use only if clearly needed. |
Clinical note
Strong CYP3A4 or P-gp inducers may decrease levels Can cause QT prolongation and orthostatic hypotension.
| Placental transfer | Paliperidone crosses the placenta; fetal plasma concentrations may reach 50-100% of maternal levels. |
| Breastfeeding | Paliperidone is excreted into breast milk in small amounts; relative infant dose estimated <5%. Monitor infant for sedation, poor feeding, and extrapyramidal effects. Consider benefits of breastfeeding versus potential risks. |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Paliperidone is not approved for the treatment of dementia-related psychosis.
| Common Effects | Abnormal involuntary movements Dizziness Nystagmus involuntary eye movement Sleepiness Tremors |
| Serious Effects | Tardive dyskinesia, Neuroleptic malignant syndrome, QT interval prolongation, Stroke (in elderly patients with dementia-related psychosis), Hyperglycemia and diabetes mellitus, Hyperprolactinemia, Orthostatic hypotension, Seizures, Leukopenia, neutropenia, and agranulocytosis |
Hypersensitivity to paliperidone or risperidoneConcurrent use with strong CYP3A4 inducers (e.g., carbamazepine, rifampin) may reduce efficacy
| Precautions | Increased mortality in elderly patients with dementia-related psychosis, Cerebrovascular adverse events (including stroke) in elderly dementia patients, Neuroleptic Malignant Syndrome (NMS), Tardive dyskinesia, Metabolic changes: hyperglycemia, diabetes mellitus, dyslipidemia, weight gain, Hyperprolactinemia, Orthostatic hypotension and syncope, Leukopenia, neutropenia, and agranulocytosis, Seizures, Potential for cognitive and motor impairment, Dysphagia, QT prolongation |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Limited human data; animal studies show increased fetal malformations (cleft palate, neural tube defects) at doses ≥ 2.5 mg/kg/day. Second/third trimesters: Risk of extrapyramidal symptoms and withdrawal (agitation, hypertonia, tremors) in neonates after third trimester exposure. Use only if benefit > risk. |
| Fetal Monitoring | Maternal: Blood pressure, weight, blood glucose, prolactin levels, EPS symptoms. Fetal/neonatal: Growth (ultrasound for IUGR if prolonged use), neonatal adaptation (therapeutic hypothermia protocols not needed; observe for EPS and respiratory depression). |
| Fertility Effects | Paliperidone elevates prolactin levels, which may suppress hypothalamic-pituitary-gonadal axis, causing menstrual irregularities, anovulation, and reversible infertility. Effects are dose-dependent and may persist after discontinuation. |
| Food/Dietary | Grapefruit and grapefruit juice may increase paliperidone concentrations; avoid excessive consumption. High-fat meals may increase absorption of the oral formulation; take consistently with or without food. Avoid alcohol and cannabis due to additive CNS depression. |
| Clinical Pearls | Paliperidone is the active metabolite of risperidone, so similar adverse effect profile. It is available as an extended-release oral formulation (once daily) and as a long-acting injectable (monthly or quarterly). Dose adjustments needed in renal impairment (creatinine clearance <50 mL/min). Titrate slowly to minimize orthostatic hypotension. Monitor for QT prolongation, especially with electrolyte disturbances or concurrent QT-prolonging drugs. Weight gain and metabolic syndrome are significant concerns; monitor weight, glucose, and lipids regularly. Prolactin elevation is common; monitor for galactorrhea, amenorrhea, gynecomastia, or sexual dysfunction. |
| Patient Advice | Take the oral tablet once daily with water, with or without food; do not chew or crush. · Do not stop taking abruptly; risk of withdrawal symptoms or relapse. · Avoid alcohol and central nervous system depressants due to additive sedation. · Report symptoms like dizziness, fainting, rapid heartbeat, or prolonged erection. · Notify your doctor about any new medications, including over-the-counter and supplements. · May cause drowsiness; avoid driving until you know how the drug affects you. · Stay hydrated and avoid overheating (dehydration may increase orthostatic hypotension). · Inform your doctor if pregnant, planning pregnancy, or breastfeeding. · For injectable: adhere to scheduled appointments; missed doses require special instructions. |